Disease Markers / 2015 / Article / Tab 1 / Review Article
Clinicopathologic and Prognostic Value of Serum Carbohydrate Antigen 19-9 in Gastric Cancer: A Meta-Analysis Table 1 Baseline characteristics and quality of the included studies.
Study Country Number of patients (M/F) Sample time Age mean ± SD/median (range) Rate of CA 19-9 Follow-up mean ± SD/median (range) Outcome measured Study quality
Huang et al. [9 ] China 363 (266/97) Preoperative 60.67 ± 11.91 67/354 Range: 41–88 DFS, OS 6 Jo et al. [10 ] Korea 1178 (773/405) Preoperative + postoperative 56 (20–88) 449/1187 28.2 (10.8–102.5) OS 7 Ye et al. [11 ] China 117 (72/45) Preoperative 63 (28–86) NR 38 (4–62) DFS, OS 7 Yajima et al. [20 ] Japan 23 (16/7) Preoperative 53–86 11/23 Max: 36 OS 4 Wang et al. [21 ] China 439 (319/120) NR NR 123/307 NR OS 5 Turkoz et al. [22 ] Turkey 176 (119/57) NR 57.8 ± 12.9 56/176 27.5 (1–56.5) OS 6 Tian et al. [23 ] China 181 (121/60) Preoperative Mean: 59.5 31/181 Max: 60 OS 6 Mohri et al. [24 ] Japan 123 (38/85) NR 66 (18–94) 47/123 Median: 9.3 OS 6 Kanda et al. [25 ] Japan 238 (179/59) Preoperative 65.3 ± 11.7 44/238 Max: 60 DSS 6 Choi et al. [29 ] Korea 488 (333/155) Preoperative Range: 27–85 163/488 Max: 44 DFS, OS 6 Mittal et al. [26 ] Nepal 40 (27/13) Preoperative NR 16/40 Max: 60 OS 6 Li et al. [27 ] China 1501 (1073/428) Preoperative 58.96 ± 11.93 284/1501 Max: 60 OS 6 Kwon et al. [28 ] Korea 102 (41/61) Postoperative NR 79/102 Max: 144 OS 6 Liu et al. [30 ] China 273 (192/81) Preoperative 56 ± 12 87/273 Median: 61.2 OS 6 Jiang et al. [31 ] Japan 1710 (1157/553) Preoperative NR 151/1557 43 (1–123) OS 7 Emoto et al. [32 ] Japan 102 (54/48) NR 57 (28–79) 37/102 Max: 48 OS 5 Schauer et al. [33 ] Germany 120 (60/60) Preoperative Mean: 57.7; range: 28–83 36/120 38 (2–120) OS 6 Kim et al. [34 ] Korea 167 (108/59) Postoperative NR 21/167 59.6 ± 12.7; 60.7 (9.8–84.8) DFS 6 Dilege et al. [35 ] Turkey 75 (47/28) Preoperative NR 25/75 24 (6–74) OS 6 Zhang et al. [36 ] China 166 (116/50) Preoperative 58 (24–85) 27/166 Median: 18 OS, DFS 5 Yamashita et al. [37 ] Japan 382 (263/119) Preoperative Mean: 59; range: 21–86 39/382 Mean: 45; range: 0–60 DSS 7 Ucar et al. [38 ] Turkey 95 (63/32) Preoperative 58 ± 10 39/95 Median: 18 OS 5 Yamashita et al. [39 ] Japan 128 (86/42) Preoperative Mean: 59; range: 21–86 24/128 Max: 60 DSS 7 Shimizu et al. [40 ] Japan 40 (28/12) Preoperative Mean: 60.6; range: 28–86 4/40 31.7 (1–48) OS 6 Louhimo et al. [41 ] Finland 146 (73/73) Preoperative 63.8 (31.6–88.4) 45/146 13.4 (0–166.8) DSS 7 Nakagoe et al. [42 ] Japan 218 (144/74) Preoperative NR 45/218 62.3 (1.3–117.3) DSS 7 Lai et al. [43 ] Taiwan 192 (120/72) Preoperative NR 31/192 Mean: 58; range: 6–182 DFS 6
Duraker and Elk [46 ] Turkey 168 (116/52) Preoperative NR 53/168 Max: 50 OS 6 Ishigami et al. [44 ] Japan 549 (386/168) Preoperative NR 109/549 42 (12–76) OS 5 Gaspar et al. [45 ] Spain 82 (55/27) Preoperative 63 ± 12 27/82 Median: 16 OS 5 Ychou et al. [47 ] France 52 (40/12) Preoperative 62 ± 12.3 26/52 Max: 48 OS 5 Kochi et al. [48 ] Japan 435 (317/118) preoperative + postoperative 61.9 (20–90) 95/435 Max: 100 DFS 6 Marrelli et al. [49 ] Italy 153 (95/58) Preoperative 69 ± 10 53/153 74 ± 10 OS 7 Tocchi et al. [50 ] Italy 59 (40/19) Preoperative Mean: 64.3; range: 31–84 23/59 Max: 60 OS 7 Tachibana et al. [51 ] Japan 196 (136/60) Preoperative NR 13/192 NR DSS 6 Nakajima et al. [52 ] Japan 110 (75/35) Preoperative 63 ± 10 29/105 Max: 36 OS 5 Kodera et al. [53 ] Japan 663 (432/231) Preoperative NR 106/663 Max: 50 OS 5 Ikeda et al. [54 ] Japan 158 (99/59) Preoperative NR 42/158 Max: 36 OS 5
Note. CA 19-9: carbohydrate antigen 19-9; DFS: disease-free survival; DSS: disease-specific survival; max: the maximum of follow-up time; M/F: male/female; NR: not reported; OS: overall survival; SD: standard deviation.
